- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 3.3 Certificate of Amendment to Amended and Restated Certificate of Incorporation
- 10.25 Asset Purchase Agreement
- 10.34 Lease Agreement - 770 Lindaro Street
- 10.35 Lease Agreement - 790 Lindaro Street
- 21.1 Subsidiaries of Biomarin Pharmaceutical Inc.
- 23.1 Consent of KPMG LLP
- 23.2 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A)/15D-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A)/15D-14(A)
- 32.1 Certification of CEO and CFO Pursuant to Section 906
- 99.1 Biomarin/genzyme LLC Consolidated Financial Statements
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
BioMarin Pharmaceutical Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-168552, 333-136963, 333-84787, and 333-85368) on Form S-8 of BioMarin Pharmaceutical Inc. and subsidiaries of our reports dated February 22, 2012, with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of operations, changes in stockholders’ equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2011, and the effectiveness of internal control over financial reporting as of December 31, 2011, which reports appears in the December 31, 2011 annual report on Form 10-K of BioMarin Pharmaceutical Inc. and subsidiaries.
/s/ KPMG LLP
San Francisco, California
February 22, 2012